GTF2B and cancer: The most active TRMN, TGAARFDEF encoded in the Gtf2b gene, which elicits the most potent and complete tumor rejection in all mice immunized (Figure 2), has a moderate predicted IC50 (to Dd); peptides with this level of moderate affinity for MHC I have been traditionally excluded as candidate MHC I–binding epitopes, including cancer neoepitopes.